Could a Mitochondria-Boosting drug help save sight in glaucoma?

NCT ID NCT06437639

Completed Disease control Sponsor: Pharmasoft Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 4 trial tested the drug Mexidol in 80 people with advanced primary open-angle glaucoma. The goal was to see if the drug could improve the function of mitochondria in cells and protect the optic nerve. Participants were randomly assigned to receive Mexidol or standard care, and researchers measured changes in cell energy levels and vision over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mexidol (ethylmethylhydroxypyridine succinate)
What this could lead to: If it works, this could point toward a way to protect the optic nerve in glaucoma patients, potentially slowing vision loss.
What could go wrong: This is a small, completed Phase 4 trial with only 80 participants, so results may not apply to everyone. The main focus is on cell-level changes, not direct vision improvement, and the drug may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY OPEN ANGLE GLAUCOMA (POAG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma inborn mitochondrial metabolism disorder open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY OPEN ANGLE GLAUCOMA (POAG)

Contacts and locations

Locations

Tyumen Scientific Center of the Russian Academy of Sciences

Tyumen, Russian Federation, 625026, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.